The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site. Please see our Subscription Terms and Conditions.

All material subject to strictly enforced copyright laws. © 2021 Euromoney, a part of the Euromoney Institutional Investor PLC.

A harder ride for R&D

The introduction of International Financial Regulatory Standards (IFRS) in January is the big bang for accountancy. Public companies in the European Union will switch to new international rules that enable more precise cross-border comparison.

But the rules will affect different industries in different ways. In the case of drugs and technology companies, the expensing of share options issued to staff and the capitalization of development are likely to be the biggest changes. The problem is that while the new rules on options are welcome and bring clarity to a murky area, the rules on development could make a muddle of an area that is currently relatively clear.

Option expensing will certainly affect the financial statements of tech and pharma companies – both of which have been heavy users of options. If IFRS had been in force last year for example, German enterprise resource software company SAP's earnings would have been reduced by 11% and mobile phone maker Nokia's by 7%.

Drugs companies would have been less hard hit as they have issued fewer options than tech companies. But the average hit to their earnings would still have been of the order of 5%.

You have reached premium content. Please log in to continue reading.

Read beyond the headlines with Euromoney

For over 50 years, our readers have looked to Euromoney to stay informed about the issues that matter in the international banking and financial markets. Find out more about our different levels of access below.


Unlimited access to and

Expert comment, long reads and in-depth analysis interviews with senior finance professionals

Access the results of our market-leading annual surveys across core financial services

Access the results of our annual awards, including the world-renowned Awards for Excellence

Your print copy of Euromoney magazine delivered monthly

£73.75 per month

Billed Annually


Unlimited access to and, including our top stories, long reads, expert analysis, and the results of our annual surveys and awards

Sign up to any of our newsletters, curated by our editors


Already a user?

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree